Abivax ADR [NASDAQ: ABVX] gained 586.00% on the last trading session, reaching $68.6 price per share at the time.
Abivax ADR represents 63.35 million in outstanding shares, while the company has a total market value of $4.35 billion with the latest information. ABVX stock price has been found in the range of $62.51 to $71.35.
If compared to the average trading volume of 416.25K shares, ABVX reached a trading volume of 27681353 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Abivax ADR [ABVX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABVX shares is $68.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABVX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Abivax ADR shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 23, 2025. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Equal-Weight. The new note on the price target was released on March 20, 2025, representing the official price target for Abivax ADR stock. Previously, the target price had yet another raise to $33, while JMP Securities analysts kept a Mkt Outperform rating on ABVX stock.
The Price to Book ratio for the last quarter was 103.41, with the Price to Cash per share for the same quarter was set at 2.35.
Trading performance analysis for ABVX stock
Abivax ADR [ABVX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 594.33. With this latest performance, ABVX shares gained by 1022.75% in over the last four-week period, additionally plugging by 976.92% over the last 6 months – not to mention a rise of 837.16% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABVX stock in for the last two-week period is set at 98.44, with the RSI for the last a single of trading hit 7.39, and the three-weeks RSI is set at 3.62 for Abivax ADR [ABVX]. The present Moving Average for the last 50 days of trading for this stock 8.52, while it was recorded at 21.81 for the last single week of trading, and 7.89 for the last 200 days.
Abivax ADR (ABVX) Capital Structure & Debt Analysis
According to recent financial data for Abivax ADR. ( ABVX), the Return on Equity (ROE) stands at -147.48%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -66.45%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Abivax ADR’s Return on Invested Capital (ROIC) is -197.95%, showcasing its effectiveness in deploying capital for earnings.
Abivax ADR (ABVX) Efficiency & Liquidity Metrics
Based on Abivax ADR’s (ABVX) latest financial statements, the Debt-to-Equity Ratio is 2.37%, indicating its reliance on debt financing relative to shareholder equity.
Abivax ADR (ABVX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Abivax ADR. (ABVX) effectively leverages its workforce, generating an average of -$2763043.48 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.82% and a Quick Ratio of 1.82%, indicating strong ability to cover short-term liabilities.
Abivax ADR [ABVX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABVX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abivax ADR go to 4.19%.
An analysis of Institutional ownership at Abivax ADR [ABVX]
There are presently around $50.19%, or 50.19% of ABVX stock, in the hands of institutional investors. The top three institutional holders of ABVX stocks are: TCG CROSSOVER MANAGEMENT, LLC with ownership of 6.06 million shares, which is approximately 14.0635%. DEEP TRACK CAPITAL, LP, holding 4.18 million shares of the stock with an approximate value of $$55.26 million in ABVX stocks shares; and DEEP TRACK CAPITAL, LP, currently with $$32.68 million in ABVX stock with ownership which is approximately 5.7405%.
